VivoSeq
Other

Nasal Polyps

0

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Nasal Polyps is an early-stage landscape with 0 programs across 2 companies. The most active players are Sanofi, GSK.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

0 programs

PreclinicalGSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed8 · 80%
Unknown status1 · 10%
Recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

Complete Remission After Treatment With Biologics for Nasal Polyps
Recruiting·—·Phase 4·NCT07268313·66 enrolled
Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps
Completed·Sanofi logoSanofi·Phase 3·NCT02898454·448 enrolled
NAsal Polyps: Inflammatory & Molecular Phenotyping of Responders to Benralizumab
Completed·HHumanitas Clinical and Research Center·Phase 3·NCT04185012·14 enrolled
A Comparison of Beclomethasone Aqueous Spray and Aerosol Delivery Systems in Nasal Polyps
Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT00788463·30 enrolled
Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video
Completed·OOptinose US Inc.·Phase 3·NCT03591068·11 enrolled
Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps
Completed·IIntersect ENT·Phase 2/3·NCT01732536·100 enrolled
A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps
Completed·Sanofi logoSanofi·Phase 3·NCT02912468·276 enrolled
Effect of Mepolizumab in Severe Bilateral Nasal Polyps
Completed·GSK logoGSK·Phase 3·NCT03085797·414 enrolled
Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292)
Completed·—·Phase 3·NCT00378378·127 enrolled
Omalizumab Efficacy in Patients With Refractory Nasal Polyps
Unknown status·SShiraz University of Medical Sciences·Phase 4·NCT05405478·2 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)